A small cap healthcare company, whose stock has zoomed up 7x since the March lows, has embarked upon the race to undertake initial study of its drug candidates RECCE® 327 and RECCE® 529. The company’s two leading candidates are being te...
Australia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed globally renowned cancer and Chimeric Antigen Receptor-T (CAR-T) expert, Professor Phillip Darcy of Peter MacCallum Cancer Centre, to its Scientific ...
Summary Kazia Therapeutics’ paxalisib awarded Rare Pediatric Disease Designation by the US FDA. With the RPDD grant, Kazia Therapeutics may now be eligible to receive a rare pediatric disease priority review voucher if paxalisib gets appr...
COVID-19 pandemic has stress-tested the world, and so far, affected more than 18.61 million people including 702,642 reported deaths (as per WHO 3:17 PM CEST, 6 August 2020). The Australian government’s response to the spread of SAR-C...
Summary The healthcare sector has been a bright spot in the otherwise dull IPO market in 2020 with seven IPOs already and more in the pipeline. 4DMedical, the Melbourne-based MedTech player, is the latest entrant with ASX listing slated for 7 A...
Summary The periodic return on a stock is the major determinator for an investor to make an investment in it, be it in the form of dividends or capital appreciation. In the last 3 months period, GTG has given a positive return of 100% to the in...
Summary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose level of 35 mg/m2 PTX-200. Phase 1b study of PTX-200 at a dose of 25 mg/m2 demonstrated no dose-limiting toxicities and therapy was better tole...
Summary Cann Group Limited continues robust commercial momentum in the June quarter of FY20. During FY20 June quarter, AusCann delivered first products of its controlled-dose capsules. Althea reported strong growth despite COVID-19 disruption ...
Summary Australian Government’s response towards containing the Virus crisis was deemed successful worldwide. Amid the pandemic, healthcare companies supporting the healthcare regime through equipment and software solutions have rec...
Summary Pro Medicus stock has gained over 4,6000%, from once trading at 50 cents per share to ~$24 per share, at present. PME’s Radiology platform Visage 7 has been the catalyst for the success of the Company, which allows medical images ...
Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)
